The Gada Group, a consolidated entity, was born from the merger of companies that were firmly rooted in the territory and specialized in the supply of medical devices and the provision of integrated health services.
Gada Spa, the holding company of the Group, manages the activities of all the commercial and service companies controlled, with particular reference to the definition of the commercial and financial strategy and the provision of all related support services.
Click on the icon to download the pdf
Click on the icon to download the pdf
The Corporate Governance structure that the GADA Group has adopted reflects the organizational model made up of the following bodies:
GADA companies are led by a management team with long experience in the sector, that is committed to ensuring the highest level of service to our customers, partners and employees.
President of Gada and part of Principia’s investment team, he has almost twenty years of experience in extraordinary finance operations, both at UBI Banca and in a financial boutique specializing in extraordinary finance operations. He is a member of the board of directors of companies operating both in the Healthcare sector and in other commercial sectors.
Antonio Biagio De Marinis joined the GADA group in November 2004 as a financial advisor. He is the CEO of the GADA Group and a member of the Board of Directors of different companies within the group. Before joining GADA, he gained over 12 years of experience in the accounting and tax field, and has served as an advisor for two of the group’s founding companies since 1995. He holds a degree in Economics and is a Chartered Accountant and Registered Auditor in the professional register.
GADA Executive Vice President
Davide Ciattoni is the Executive Vice President of GADA and one of the members of the group’s Board of Directors. He has over 30 years of experience with world leading companies in the medical technology sector. He started his experience in the regional sales of Terumo products. He founded Cormed Srl and co-founded Biocor Srl, EPS SpA, Nihon Medical Italia SpA and Nefroline SpA. During his career he has contributed to the introduction of various innovative technologies that have transformed the Italian healthcare market. He is one of the founders of the GADA group.
A member of the Gada board of directors, she first worked at PWC and later on with the Principia investment team. She has a degree in Finance from Luigi Bocconi University.
Paolo D. Siviero
Fund Manager of the PRINCIPIA III Fund. From 2008 to 2014 he was head of the Drug Strategy and Policies Division of AIFA (Italian Medicines Agency), with direct responsibility for the activities of price definition and reimbursement of pharmaceuticals , the Health Technology Assessment and the control of pharmaceutical expenditure.
During the same period he held positions of international importance. Some of these include, for example, participation in the Board of Directors for EMA (European Medicines Agency) as an Italian representative, serving as president of the MEDEV group (Medicine Evaluation Committee), an association which brings together representatives of the main European Healthcare Systems, and serving as an Italian expert, a designation from the Italian Ministry of Health, within the European HTA Network (network for health technology assessment).
He previously collaborated with the National Research Council in the fields of technology transfer, intellectual property management and knowledge management. 2nd Level Master, cum laude, in Regulatory Sciences of Medicine (La Sapienza University, Rome)
EPS Vice President
Alessandro Pellegrinelli is the Vice President of EPS SpA. He began his career in 1982 at Biolabor in Ancona, a regional distributor of laboratory and clinical analysis technologies, where he was the director of sales. He co-founded Biocor Srl, EPS SpA, Nihon Medical Italia SpA and Nefroline SpA. He is one of the founders of the GADA group. He graduated in Economics and Business in Ancona.